TABLE 1. In vitro susceptibilities of Trichosporon spp. and Blastoschizomyces capitatus isolates to fluconazole and voriconazole as determined by CLSI disk diffusion testing a (67)
|
Species
|
Fluconazole b |
Voriconazole b |
||||
|
No. of isolates tested |
% S |
% R
|
No. of isolates tested |
% S |
% R
|
|
|
Trichosporon spp.c |
443 |
84.7 |
9.0 |
422 |
95.0 |
2.4 |
|
T. beigelii/T. cutaneum |
125 |
77.6 |
12.0 |
123 |
83.7 |
12.2 |
|
T. mucoides |
51 |
94.1 |
0.0 |
51 |
100.0 |
0.0 |
|
T. asahii |
53 |
79.2 |
15.1 |
53 |
92.5 |
7.5 |
|
T. inkin |
13 |
92.3 |
7.7 |
13 |
100.0 |
0.0 |
|
T. ovoides |
3 |
100.0 |
0.0 |
3 |
100.0 |
0.0 |
|
Blastoschizomyces capitatus |
86 |
81.4 |
11.6 |
86 |
91.9 |
3.5 |
a: Isolates were obtained from 124 institutions. b: Fluconazole and voriconazole disk diffusion testing was performed in accordance with CLSI document M44-A. The interpretive breakpoints (zone diameters) were as follows: S, 19 mm (fluconazole) and 17 mm (voriconazole); R, 14 mm (fluconazole) and 13 mm (voriconazole). c. Trichosporon species not otherwise identified.
TABLE 2. In vitro susceptibilities of fluconazole-resistant isolates of Trichosporon spp. and Blastoschizomyces capitatus to voriconazole as determined by CLSI disk diffusion testing a (67)
|
|
No. of isolates tested |
% S |
% SDD |
% R
|
|
Trichosporon spp.b |
38 |
55.3 |
21.1 |
23.7 |
|
T. beigelii / T. cutaneum |
15 |
13.3 |
6.7 |
80.0 |
|
T. asahii |
8 |
50.0 |
0.0 |
50.0 |
|
T. inkin |
1 |
100.0 |
0.0 |
0.0 |
|
Blastoschizomyces capitatus |
10 |
60.0 |
10.0 |
30.0 |
a: Isolates were obtained from 124 institutions. The zone diameters for the voriconazole disk diffusion susceptibility categories were as follows: S, 17 mm; SDD, 14 to 16 mm; R, 13 mm. b: Trichosporon species not otherwise identified.
Table 3. In vitro susceptibilities of Trichosporon spp and B. capitatus to antifungal
agents (5)
|
Species |
Antifungal agent |
No of isolates tested |
MIC (μg/ml) |
||
|
Range |
50% |
90% |
|||
|
T. asahii |
Amphotericin B |
43 |
1-8 |
4 |
4 |
|
|
Fluconazole |
43 |
0.25-16 |
2 |
8 |
|
|
Itraconazole |
43 |
0.06-4 |
.5 |
1 |
|
|
Ravuconazole |
10 |
0.25-0.5 |
0.25 |
0.5 |
|
|
Posaconazole |
24 |
0.06 - >16 |
0.12 |
N/A |
|
|
Voriconazole |
10 |
0.25-2 |
0.5 |
2 |
|
|
Micafungin |
10 |
>64 |
>64 |
>64 |
|
Non - T. asahii |
Amphotericin B |
15 |
0.6-1 |
0.25 |
N/A |
|
|
Fluconazole |
15 |
0.5-4 |
2 |
N/A |
|
|
Itraconazole |
15 |
0.03-0.5 |
0.012 |
N/A |
|
|
Ravuconazole |
15 |
0.03 - >16 |
0.5 |
N/A |
|
|
Posaconazole |
15 |
0.03-0.5 |
0.12 |
N/A |
|
|
Voriconazole |
15 |
0.0-0.25 |
0.06 |
N/A |
|
B. capitatus |
Amphotericin B |
23 |
0.06-0.25 |
0.12 |
0.12 |
|
|
Fluconazole |
23 |
1-32 |
8 |
8 |
|
|
Itraconazole |
23 |
0.03-0.5 |
0.12 |
0.25 |
|
|
Flucytocine |
23 |
0.12-16 |
0.12 |
4 |
|
|
Posaconazole |
25 |
N/A |
0.12 |
0.25 |
|
|
Voriconazole |
23 |
0.03-0.5 |
0.25 |
0.25 |
|
|
Caspofungin |
25 |
N/A |
16 |
>16 |
MIC: minimum inhibitory capacity, N/A: not available
Figure 1
Figure 2
